HAVCR2 and neoplasm: TIM-3, also known as hepatitis A virus cell receptor 2 (HAVCR2) or CD366, is another promising inhibitory receptor among numerous emerging immune checkpoints and has achieved initial anti-tumor effects in clinical trials of its monotherapy or combination with anti PD-1/PD-L1 drugs [96].